The US Food and Drug Administration (FDA) has relaxed a limitation on advertising and promotion for certain COVID-19 drugs with emergency use authorizations (EUAs). The agency said that “truthful and non-misleading” advertising and promotion of COVID-19 therapeutics could benefit the public health, though some caveats to how the drugs can be promoted still apply.
In a memorandum dated 27 October, first reported by AgencyIQ, FDA laid out a new policy giving sponsors of EUA products more leeway to promote their products. Unlike drugs and biologics that are approved via traditional pathways, when issuing an EUA, FDA can place conditions on advertising and promotional materials that relate to a drug’s emergency use…
